Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.

Pfizer (NYSE:PFE) has signed an exclusive global licensing deal with China’s 3SBio for the development of its cancer drug candidate, SSGJ-707. SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Two drugs. Two strategies. One industry in the middle of a rewiring.

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

PD-1/VEGF bispecifics are becoming too important to ignore, and the 3SBio deal is a very cheap way to participate And while some may criticize Pfizer for a lack of imagination, I like this deal ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Under terms of the deal, both companies will co-develop and co-commercialize BNT327 for multiple solid tumors, with the ...